NRAS and cancer: Our studies here suggest that activation of Jak-Stat may serve as a universal mechanism through which oncogenic N-Ras dysregulates HSPC function and promote leukemia; therefore, inhibiting Jak/Stat signaling may have therapeutic benefit in RAS mutant cancers.